newsfilter
← Latest News
Business Wire·

Rallybio Reports Fourth Quarter and Full Year 2023 Financial Results

-- Received Protocol Assistance Feedback from European Medicines Agency on the Phase 2 Study for RLYB212; Company to Proceed Forward with Clinical Trial Application Process in Europe -- -- Phase 2 Dose Confirmation